The Scientist

» IPO

Most Recent

image: Another CRISPR Biotech Goes Public

Another CRISPR Biotech Goes Public

By | September 12, 2016

CRISPR Therapeutics, the company started by a pioneer of the gene editing technology, plans to raise $90 million from an initial public offering.

0 Comments

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

image: Biotech Stocks Take a Hit

Biotech Stocks Take a Hit

By | September 30, 2015

Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.

1 Comment

image: Biotech Terminates IPO

Biotech Terminates IPO

By | August 15, 2014

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 

0 Comments

image: Biotech IPOs Surge

Biotech IPOs Surge

By | August 23, 2013

The drought has ended for biotech companies seeking to join the public market, but whether this upward swing will last is anybody’s guess.

0 Comments

image: Braving the IPO Drought

Braving the IPO Drought

By | March 1, 2012

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

0 Comments

Popular Now

  1. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  2. Sequencing Reveals Genomic Diversity of the Human Brain
  3. How Plants Evolved Different Ways to Make Caffeine
  4. What Sensory Receptors Do Outside of Sense Organs
RayBiotech